Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma

被引：0
|
作者：
A Ray
D S Das
Y Song
T Hideshima
Y-T Tai
D Chauhan
K C Anderson
机构：
[1] The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center,Department of Medical Oncology
[2] Dana-Farber Cancer Institute,undefined
[3] Harvard Medical School,undefined
来源：
Leukemia | 2018年 / 32卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：843 / 846
页数：3
相关论文
共 50 条
  • [41] Tusamitamab ravtansine induces immunogenic cell death and synergizes with anti-PD-1 or anti-PD-L1 antibody combination in solid tumor
    Nicolazzi, Celine
    Lefebvre, Anne-Marie
    Moindrot, Nicolas
    Larois, Christelle
    Classe, Marion
    Sidhu, Sukhvinder
    CANCER RESEARCH, 2024, 84 (06)
  • [42] MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity
    Xiong, Wei
    Deng, Huanghao
    Huang, Changkun
    Zen, Chong
    Jian, Chengzhu
    Ye, Kun
    Zhong, Zhaohui
    Zhao, Xiaokun
    Zhu, Liang
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2019, 1865 (02): : 454 - 463
  • [43] Intraperitoneal anti-PD-L1 increases survival in a novel ovarian cancer model and its in vivo efficacy is influenced by baseline anti-tumor immunity of the host
    Mony, Jyothi
    Zhang, Lixin
    Tirodkar, Tejas
    Elishaev, Esther
    Brozick, Joan
    Edwards, Robert P.
    Vlad, Anda M.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [44] ANTI-PD-L1/IL-15 KD033 ACTIVATED MACROPHAGES AND INDUCED ANTI-TUMOR IMMUNITY IN THE TUMOR-MICROENVIRONMENT
    Martomo, Stella
    Wang, George
    Polonskaya, Zhanna
    Luna, Xenia
    Lu, Dan
    Patel, Jeegar
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A681 - A681
  • [45] Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
    Pei Zhang
    Yang Du
    Hua Bai
    Zhijie Wang
    Jianchun Duan
    Xin Wang
    Jia Zhong
    Rui Wan
    Jiachen Xu
    Xiran He
    Di Wang
    Kailun Fei
    Ruofei Yu
    Jie Tian
    Jie Wang
    BMC Medicine, 20
  • [46] Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
    Zhang, Pei
    Du, Yang
    Bai, Hua
    Wang, Zhijie
    Duan, Jianchun
    Wang, Xin
    Zhong, Jia
    Wan, Rui
    Xu, Jiachen
    He, Xiran
    Wang, Di
    Fei, Kailun
    Yu, Ruofei
    Tian, Jie
    Wang, Jie
    BMC MEDICINE, 2022, 20 (01)
  • [47] M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
    Knudson, Karin M.
    Hicks, Kristin C.
    Luo, Xiaoling
    Chen, Jin-Qiu
    Schlom, Jeffrey
    Gameiro, Sofia R.
    ONCOIMMUNOLOGY, 2018, 7 (05):
  • [48] Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors (vol 32, pg 1932, 2018)
    Bae, Jooeun
    Hideshima, Teru
    Tai, Yu-Tzu
    Song, Yan
    Richardson, Paul
    Raje, Noopur
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    LEUKEMIA, 2024, 38 (05) : 1189 - 1190
  • [49] Targeting the intrinsic signaling of PD-L1 in human monocytes by a novel PD-L1 antibody to promote anti-tumor immunity.
    Hsu, Michelle A.
    Liu, Xin
    Barham, Whitney
    Hirdler, Jacob
    Mao, Zhiming
    Lucien, Fabrice
    Dong, Haidong
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [50] BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
    Wang, Huijin
    Liu, Guangyao
    Jin, Xinghan
    Song, Shenglei
    Chen, Songyao
    Zhou, Peiqing
    Li, Huan
    Liang, Jianming
    Li, Bo
    Zhang, Changhua
    He, Yulong
    JOURNAL OF CANCER, 2022, 13 (06): : 2126 - 2137
12345